Estelle Gandjbakhch

Estelle Gandjbakhch

Auto-generated profile, based on publicly available information

Estelle Gandjbakhch

Sorbonne Université, APHP, La Pitié Salpetrière University Hospital , Paris

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2025 in European Heart Journal
Verified
Journal Article
Closed access
JSJeanette Schulz-Menger
Jeanette Schulz-Menger
VCValentino Collini
Valentino Collini
JGJan Wolfgang Gröschel
Jan Wolfgang Gröschel
YAYehuda Adler
Yehuda Adler
ABAntonio Brucato
Antonio Brucato
AKAmayak Kevorkov
Amayak Kevorkov

1 November 2016 in JACC
Verified
Journal Article
Closed access
SKSaurabh Kumar
Saurabh Kumar
SBSamuel H. Baldinger
Samuel H. Baldinger
EGEstelle Gandjbakhch
Estelle Gandjbakhch
PMPhilippe Maury
Philippe Maury
JSJean-Marc Sellal
Jean-Marc Sellal
NLNeal K. Lakdawala
Neal K. Lakdawala

23 February 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
JSJoe-Elie Salem
Joe-Elie Salem
MBMarie Bretagne
Marie Bretagne
BABaptiste Abbar
Baptiste Abbar
SLSarah Leonard-Louis
Sarah Leonard-Louis
SEStéphane Ederhy
Stéphane Ederhy
YAYves Allenbach
Yves Allenbach
Immune-checkpoint-inhibitor (ICI)–associated myotoxicity involves the heart (myocarditis) and skeletal muscles (myositis), which frequently occur concurrently and are highly fatal. We report the results of a strategy that included identification of individuals with severe ICI myocarditis by also screening for and managing concomitant respiratory muscle involvement with mechanical ventilation, as well as treatment with the CTLA4 fusion protein abatacept and the JAK inhibitor ruxolitinib. Forty cases with definite ICI myocarditis were included with pathologic confirmation of concomitant myositis in the majority of patients. In the first 10 patients, using recommended guidelines, myotoxicity-related fatality occurred in 60%, consistent with historical controls. In the subsequent 30 cases, we instituted systematic screening for respiratory muscle involvement coupled with active ventilation and treatment using ruxolitinib and abatacept. The abatacept dose was adjusted using CD86 receptor occupancy on circulating monocytes. The myotoxicity-related fatality rate was 3.4% (1/30) in these 30 patients versus 60% in the first quartile (P < 0.0001). These clinical results are hypothesis-generating and need further evaluation. Significance: Early management of respiratory muscle failure using mechanical ventilation and high-dose abatacept with CD86 receptor occupancy monitoring combined with ruxolitinib may be promising to mitigate high fatality rates in severe ICI myocarditis. See related commentary by Dougan, p. 1040. This article is highlighted in the In This Issue feature, p. 1027

1 August 2018 in JACC
Verified
Journal Article
Closed access
EGEstelle Gandjbakhch
Estelle Gandjbakhch
ARAlban Redheuil
Alban Redheuil
FPFrançoise Pousset
Françoise Pousset
PCPhilippe Charron
Philippe Charron
RFRobert Frank
Robert Frank

16 April 2023 in European Heart Journal
Verified
Journal Article
Open access
PDF file
RTRoland Richard Tilz
Roland Richard Tilz
VSVanessa Schmidt
Vanessa Schmidt
HPHelmut Pürerfellner
Helmut Pürerfellner
PMPhilippe Maury
Philippe Maury
KCK R J Ulian Chun
K R J Ulian Chun
Christian-H HeegerChristian-H Heeger
Christian-H Heeger
Oesophageal fistula represents a rare but dreadful complication of atrial fibrillation catheter ablation. Data on its incidence, management, and outcome are sparse. This international multicentre registry investigates the characteristics of oesophageal fistulae after treatment of atrial fibrillation by catheter ablation. A total of 553 729 catheter ablation procedures (radiofrequency: 62.9%, cryoballoon: 36.2%, other modalities: 0.9%) were performed, at 214 centres in 35 countries. In 78 centres 138 patients [0.025%, radiofrequency: 0.038%, cryoballoon: 0.0015% (P < 0.0001)] were diagnosed with an oesophageal fistula. Peri-procedural data were available for 118 patients (85.5%). Following catheter ablation, the median time to symptoms and the median time to diagnosis were 18 (7.75, 25; range: 0–60) days and 21 (15, 29.5; range: 2–63) days, respectively. The median time from symptom onset to oesophageal fistula diagnosis was 3 (1, 9; range: 0–42) days. The most common initial symptom was fever (59.3%). The diagnosis was established by chest computed tomography in 80.2% of patients. Oesophageal surgery was performed in 47.4% and direct endoscopic treatment in 19.8% and conservative treatment in 32.8% of patients. The overall mortality was 65.8%. Mortality following surgical (51.9%) or endoscopic treatment (56.5%) was significantly lower as compared to conservative management (89.5%) [odds ratio 7.463 (2.414, 23.072) P < 0.001]. Oesophageal fistula after catheter ablation of atrial fibrillation is rare and occurs mostly with the use of radiofrequency energy rather than cryoenergy. Mortality without surgical or endoscopic intervention is exceedingly high. Summary of the POTTER-AF study results. CI, confidence interval; OR, odds ratio.

19 January 2016 in Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
SHStéphane N. Hatem
Stéphane N. Hatem
ARAlban Redheuil
Alban Redheuil
EGEstelle Gandjbakhch
Estelle Gandjbakhch
The amount of adipose tissue that accumulates around the atria is associated with the risk, persistence, and severity of atrial fibrillation (AF). A strong body of clinical and experimental evidence indicates that this relationship is not an epiphenomenon but is the result of complex crosstalk between the adipose tissue and the neighbouring atrial myocardium. For instance, epicardial adipose tissue is a major source of adipokines, inflammatory cytokines, or reactive oxidative species, which can contribute to the fibrotic remodelling of the atrial myocardium. Fibro-fatty infiltrations of the subepicardium could also contribute to the functional disorganization of the atrial myocardium. The observation that obesity is associated with distinct structural and functional remodelling of the atria has opened new perspectives of treating AF substrate with aggressive risk factor management. Advances in cardiac imaging should lead to an improved ability to visualize myocardial fat depositions and to localize AF substrates.